A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors

• Үндсэн зохиолчид: Lucas Moreno (Зохиогч), Pierre Teira (Зохиогч), James M. Croop (Зохиогч), Nicolas U. Gerber (Зохиогч), Nicolas André (Зохиогч), Isabelle Aerts (Зохиогч), Luis Gros Subias (Зохиогч), Bram De Wilde (Зохиогч), Francisco Bautista (Зохиогч), Brian Turpin (Зохиогч), Srinivasa Kunduri (Зохиогч), Ali Hamidi (Зохиогч), Tatiana Lawrence (Зохиогч), Keri A. Streby (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Frontiers Media S.A., 2023-05-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

BackgroundThe survival rates for pediatric patients with relapsed and refractory tumors are poor. Successful treatment strategies are currently lacking and there remains an unmet need for novel therapies for these patients. We report here the results of a phase 1 study of talimogene laherparepvec (T...